Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity
Statistics in Medicine · 2025-12 · 44 (28-30)
DOI: 10.1002/sim.70324 ↗At a glance
Journal article in Statistics in Medicine, published online on 2025-11-27. Written by Konstantinos Sechidis and 5 co-authors. Institution: Advanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland. Major MEDLINE topics: Precision Medicine. Cited 5 times so far (Crossref); 77 references. Funded by: Two Sigma Graduate Fellowship Fund, Citadel GQS PhD Fellowship, National Science Foundation.
Abstract (original language)
Assessing treatment effect heterogeneity (TEH) in clinical trials is crucial, as it provides insights into the variability of treatment responses among patients, influencing key decisions related to drug development. Furthermore, it can lead to personalized medicine by tailoring treatments to individual patient characteristics. This paper introduces novel methodologies for assessing treatment effects using the individualized treatment effect as a basis. To estimate this effect, we use a doubly robust (DR) learner to infer a pseudo‐outcome that reflects the causal contrast. This pseudo‐outcome is then used to perform three objectives: (1) a global test for heterogeneity, (2) ranking covariates based on their influence on effect modification, and (3) providing estimates of the individualized treatment effect. We compare the DR‐learner with various alternatives and competing methods in a simulation study, and also use it to assess heterogeneity in a pooled analysis of five Phase III trials in psoriatic arthritis (PsA). By integrating these methods with the recently proposed Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors (WATCH) workflow, we provide a robust framework for analyzing TEH, offering insights that enable more informed decision‐making in this challenging area.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Advanced Methodology and Data Science, Novartis Pharma AG, Basel, Switzerland.
- China Novartis Institutes for Bio-medical Research CO., Shanghai, China.
- Advanced Methodology and Data Science, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
- Department of Statistics, Stanford University, Stanford, California, USA.
ORCID profiles: Konstantinos Sechidis, Asher Spector, Björn Bornkamp
Funding
- Two Sigma Graduate Fellowship Fund
- Citadel GQS PhD Fellowship
- National Science Foundation
Cite
APA
Sechidis, K., Zhang, C., Sun, S., Chen, Y., Spector, A., & Bornkamp, B. (2025). Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity. Statistics in Medicine, 44(28-30). https://doi.org/10.1002/sim.70324
Vancouver
Sechidis K, Zhang C, Sun S, Chen Y, Spector A, Bornkamp B. Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity. Statistics in Medicine. 2025;44(28-30). doi:10.1002/sim.70324
BibTeX
@article{Sechidis2025,
author = {Sechidis, Konstantinos and Zhang, Cong and Sun, Sophie and Chen, Yao and Spector, Asher and Bornkamp, Björn},
title = {Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity},
journal = {Statistics in Medicine},
year = {2025},
volume = {44},
number = {28-30},
doi = {10.1002/sim.70324}
}
EUVIMED